Search Results
Your search for The A,The A matches 34190 pages
Showing 24951 - 25000
Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma
For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show...
Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
Gregory T. Armstrong, MD, MSCE, on Late Mortality in Childhood Cancer Survivors
Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discusses the findings of a landmark survivorship study (Abstract LBA2).
Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care
Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).
Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (Abstract LBA502).
Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis
Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL
Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
Matthew J. Loscalzo, LCSW, on The Effects of Gender on Patients’ Coping Strategies and Stress Management
Matthew J. Loscalzo, LCSW, of the City of Hope, discusses the ways in which a person’s gender influences how he or she reacts to and copes with a cancer diagnosis and treatment.
Jimmie C. Holland, MD, and Tammy A. Schuler, PhD, on Talking With Patients About Their Distress: A Demonstration
Jimmie C. Holland, MD, of Memorial Sloan Kettering Cancer Center, and Tammy A. Schuler, PhD, of the Association for Behavioral and Cognitive Therapies, demonstrate a dialogue between a clinician and a recently diagnosed cancer patient whose distress was discovered with the use of the Distress...
Patricia A. Ganz, MD, on Incorporating Psychosocial Services for Quality Cancer Care
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses the Institute of Medicine report on patient-centered care, its relation to psychosocial services, and the role IPOS/APOS members can play.
Christopher J. Recklitis, PhD, MPH, on The Risk of Suicide After a Cancer Diagnosis
Christopher J. Recklitis, PhD, MPH, of the Dana-Farber Cancer Institute, discusses what is known about suicide after cancer, the risks faced by prostate cancer patients within the first year after diagnosis, and challenges across the treatment trajectory
Julia H. Rowland, PhD, on The Psychosocial Challenges Cancer Survivors Face
Julia H. Rowland, PhD, of the National Cancer Institute, discusses the growing number of promising interventions to improve health and function for those living with and beyond a cancer diagnosis, as well as those who care for and about them.
Nagashree Seetharamu, MD, on Anti-Glycan Antibody Profiling in De Novo Stage IV Non Small Cell Lung Cancer
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer
Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.
Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or...
Ugo Pastorino, MD, on Reducing Lung Cancer Mortality
Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mortality by more than 25%, a benefit that is three- to fivefold greater than this type of screening...
Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).
James R. Jett, MD, on Screening With Early CDT and CT
James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, this biomarker would increase the detection of early-stage lung cancer (Abstract MINI 12.11).
Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk
Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).
Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial
Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).
Roy S. Herbst, MD, PhD, on Results From SWOG S0819
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).
Silvia Novello, MD, PhD: Lung Cancer Is a Women's Disease Too
Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.
Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC
Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of...
Eric Lim, MD, on Increasing Incidence of Non-Smoking Lung Cancer
Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more important role in diagnosing these patients at an earlier stage.
M. Catherine Pietanza, MD, on A Promising New Agent for SCLC
M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).
Cora N. Sternberg, MD, on New Targets in Renal Cell Carcinoma
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
Clifford A. Hudis, MD, on Results of the TAILORx Clinical Trial
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).
Frederic Amant, MD, PhD, on Cancer and Pregnancy
Frederic Amant, MD, PhD, of the Katholieke Universiteit Leuven, discusses the important decisions that must be made when a woman is diagnosed with cancer while pregnant: Should treatment be delayed or the pregnancy terminated?
A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer
A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of men with advanced prostate cancer (Abstracts 2510, 2530).
Matti S. Aapro, MD, on Geriatric Oncology: A Multidisciplinary Approach for Positive Outcomes
Matti S. Aapro, MD, of IMO Clinique de Genolier, offered a case presentation and a cross-disciplinary approach to finding the best way to effect a cure with minimal impact on quality of life.
Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy
Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).
Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).
Rolf A. Stahel, MD, on Results From the BELIEF Trial
Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation. The study was sponsored by The Spanish Lung Cancer Group and the European Thoracic Oncology...
Eduardo Bruera, MD, on Cachexia Assessment and Management State of the Art
Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).
Judith Vick, MD Candidate, and Rachelle E. Bernacki, MD, on A New Clinical Tool: The “Surprise Question”
Judith Vick, MD Candidate, of Johns Hopkins University School of Medicine, and Rachelle E. Bernacki, MD, of Dana-Farber Cancer Institute, discuss a tool that could help clinicians identify seriously ill patients who would benefit from conversations about their goals and values (Abstract 8).
Diane Portman, MD, on Integrating Palliative Care in Cancer Treatment
Diane Portman, MD, of Moffitt Cancer Center, discusses clinical pathways that embed palliative care along the spectrum of care for a variety of cancer disease states.
Lawrence H. Einhorn, MD, on Palliative Radiation for Advanced Cancer and Symptomatic Bone Metastases
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the ways in which a dedicated palliative radiation consult service can improve the quality of palliative cancer care (Abstract 110).
Amelie Harle, MD, on Aprepitant for Cough in Lung Cancer
Amelie Harle, MD, of the Christie NHS Foundation Trust, discusses a clinical trial––the first of its kind—designed to assess the efficacy of an antitussive in patients with lung cancer (Abstract 2).
Eric Roeland, MD: Toward Better Treatment for Cachexia
Given the challenges of recruiting patients for palliative care studies, Eric Roeland, MD, of the University of California, San Diego, discusses a way to increase the participation of those with cachexia, with the hope of improving treatment (Abstract 67).
Leonard Gunderson, MD, on the Presidential Symposium Lecture on Upper and Lower GI Cancers
Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse...
Bruce Minsky, MD, on Clinical Trial Results: The ASCENDE-RT Trial and a Multicenter Study on Prostate Cancer
Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).
Anthony Zietman, MD, on Accelerating Treatment: RTOG 0415 Study on Prostate Cancer
Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).
Anthony Zietman, MD, on Hormonal Therapy and Salvage Radiation: Results of RTOG 9601
Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).
Vratislav Strnad, MD, PhD, on Multicatheter Brachytherapy After Breast-Conserving Surgery
Vratislav Strnad, MD, PhD, of the University Hospital in Erlangen, discusses results from a European study comparing accelerated partial-breast irradiation using brachytherapy, to the standard treatment of whole-breast irradiation for women with low-risk breast cancer (Abstract LBA7).
Christopher Brian Allard, MD, on Prostate Cancer Risk and Regular Aspirin Use
Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).
Toni Choueiri, MD: Renal Cancer Update
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for...
Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial (French Language Version) 
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).
Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499). To see the French language version of this video, click here.
Jennifer A. Ligibel, MD, on Breast Cancer Survivorship in Young Women
Jennifer A. Ligibel, MD, of the Dana-Farber Cancer Institute, discusses the physical activity behaviors and weight changes in a study cohort of young women with breast cancer (Abstract 166).
Lewis E. Foxhall, MD, on Communication and Coordination of Survivorship Care
Lewis E. Foxhall, MD, of The University of Texas MD Anderson Cancer Center, summarizes this session in which presenters covered a range of issues, including the medical home, tools to facilitate communication with cancer survivors, EMRs, reimbursement, and coordinating care with primary care...
